‹ BackThe Newspaper EditionFront PageExit to modern site ›
Liberty Bell Report

Health & Medicine

A Daily Pill for Alzheimer's? A Viagra-Family Drug Slowed Decline in Patients Not Taking Other Dementia Medicines, but Fell Short in the Full Trial

South Korea's AriBio says its once-daily AR1001 slowed decline by 31% in a key group of early Alzheimer's patients. Experts call the results encouraging but preliminary, and warn families not to reach for Viagra.

By MICHAEL GRANTStaff Correspondent · MASSACHUSETTS · Nov 18, 3:00 AM · 3 min. read

Illustration: Photorealistic cinematic close-up of an elderly couple's hands clasped on a kitchen table beside a small white pill and a glass of water, a family photo album open nearby, warm morning window light, faces not shown, hopeful…

Illustration · Liberty Bell Report

For families watching a parent or spouse slip away to Alzheimer's disease, a simple daily pill would be welcome news. A large new trial offers a reason for cautious hope, and an important reason for patience.

South Korean drugmaker AriBio said its experimental pill AR1001 met its main goal in a prespecified group of patients who were not taking other Alzheimer's medicines, though it did not reach statistical significance across the whole trial, the company announced. The results were presented Nov. 16 at the Clinical Trials on Alzheimer's Disease conference in Boston.

What the trial found

The Phase 3 trial, called POLARIS-AD, enrolled 1,535 people with early Alzheimer's disease and gave them AR1001 or a placebo once a day for 52 weeks, BioSpace reported.

In the 604 patients who were not taking the common dementia drugs known as acetylcholinesterase inhibitors or memantine, those on AR1001 declined 31% more slowly than those on placebo, a difference of 0.44 points on the trial's main measure, according to AriBio. The Washington Post reported that the drug held off decline by a little more than three months compared with placebo over the year.

Across all 1,535 participants, however, the difference between the drug and placebo was not statistically significant. Researchers do not yet know why the benefit appeared only in the group not taking other medicines, the Post reported.

A blood-and-spinal-fluid marker of Alzheimer's disease, p-tau217, moved in the drug's favor in both groups, and the change reached statistical significance in the monotherapy group, according to AriBio. Other measures of thinking and daily function also leaned toward the drug, with larger effects in that same group.

How it works

AR1001 belongs to the same family of medicines as Viagra. Both work by blocking an enzyme called PDE5, which helps relax blood vessels and increase blood flow, the Post reported. The drug is already sold in South Korea under the name Mvix, according to the Post. If it is eventually cleared for Alzheimer's, it would be a low-dose pill taken once a day, Newser reported.

That is an important part of the appeal. A pill that can be taken at home, at the kitchen table, is far easier on older patients and their caregivers than treatments that require regular trips to a clinic.

Safety

The drug's safety record in the trial was mostly reassuring, with one caution. Serious side effects occurred at nearly the same rate in both groups, 10.0% of patients on AR1001 compared with 9.8% on placebo, AriBio reported. But side effects led 5.2% of patients on the drug to stop treatment, compared with 1.7% on placebo.

A word of warning for families

Researchers were clear on one point: people should not take Viagra or similar drugs on their own to try to treat Alzheimer's disease, the Post reported. The trial tested a specific medicine, at a specific dose, under close medical supervision. Anyone caring for a loved one with memory loss should talk with the patient's doctor before changing any medication.

Experts also urged patience. One neuroscientist told the Post that it is "early days to say much definitively". Clinical Trials Arena described the result as a Phase 3 win in the monotherapy group, while other industry coverage called the results mixed and said the miss in the full trial raises questions about the drug's broader effectiveness and its chances with regulators.

What comes next

AriBio plans to present more analyses at future scientific meetings and to discuss the full findings with the U.S. Food and Drug Administration to decide next steps. The company will ask the FDA whether the data are strong enough for approval or whether another large trial is needed, the Post reported.

Why it matters

Alzheimer's disease touches millions of American families, and nearly every one of them knows the toll it takes on those who love and care for a patient. Each new treatment that can buy time, even a few months, means more birthdays recognized, more conversations remembered and more days at home.

This result is not a cure, and it is not yet a treatment anyone can get for Alzheimer's in the United States. But it adds to growing hope that the disease can be slowed, and it points toward a simpler way to do it. For now, the best steps for families remain the familiar ones: regular checkups, attention to heart health and blood pressure, staying active and connected, and an early conversation with a doctor at the first signs of memory trouble.

Sources

  1. The Washington Post: The first pill to slow Alzheimer's could come from an unexpected place (link)
  2. AriBio (GlobeNewswire): AriBio's Oral AR1001 Meets Primary Efficacy Objective in Prespecified Monotherapy Population in Phase 3 POLARIS-AD Trial (link)
  3. BioSpace: CTAD 2026: AriBio's Alzheimer's candidate slows cognitive decline as monotherapy (link)
  4. Clinical Trials Arena: AriBio's oral Alzheimer's drug nets Phase III win (link)
  5. Newser: Viagra-Like Pill Shows Promise in Slowing Alzheimer's (link)
  6. Pharmacally: AriBio Reports Mixed Phase 3 Results for Alzheimer's Drug (link)

— 30 —

Read this story on the full website, with comments »

Also in Today’s Edition

Previous pageA New Daily Pill for Women Whose Breast Cancer Outsmarts…Turn the pageWhite House Pulls Heidi Overton's FDA Nomination on the Eve…